![FT Vest US Equity Max Buffer ETF June](/common/images/company/A_JUNM.png)
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -0.162284972412 | 30.81 | 30.87 | 30.56 | 43976 | 30.60444266 | SP |
4 | 0.14 | 0.457217504899 | 30.62 | 30.9 | 30.56 | 61043 | 30.72188595 | SP |
12 | 0.23 | 0.753357353423 | 30.53 | 31.1 | 30.47 | 94062 | 30.62808263 | SP |
26 | 0.23 | 0.753357353423 | 30.53 | 31.1 | 30.47 | 94062 | 30.62808263 | SP |
52 | 0.23 | 0.753357353423 | 30.53 | 31.1 | 30.47 | 94062 | 30.62808263 | SP |
156 | 0.23 | 0.753357353423 | 30.53 | 31.1 | 30.47 | 94062 | 30.62808263 | SP |
260 | 0.23 | 0.753357353423 | 30.53 | 31.1 | 30.47 | 94062 | 30.62808263 | SP |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관